Adam B. Greenbaum
Henry Ford Heart and Vascular Institute
Detroit
USA
Name/email consistency: high
- Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Greenbaum, A.B., Ohman, E.M., Gibson, C.M., Borzak, S., Stebbins, A.L., Lu, M., Le May, M.R., Stankowski, J.E., Emanuelsson, H., Weaver, W.D. Am. Heart J. (2007)
- Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Greenbaum, A.B., Grines, C.L., Bittl, J.A., Becker, R.C., Kereiakes, D.J., Gilchrist, I.C., Clegg, J., Stankowski, J.E., Grogan, D.R., Harrington, R.A., Emanuelsson, H., Weaver, W.D. Am. Heart J. (2006)
- Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Greenbaum, A.B., Harrington, R.A., Hudson, M.P., MacAulay, C.M., Wilcox, R.G., Simoons, M.L., Berdan, L.G., Guerci, A., Cokkinos, D.V., Kitt, M.M., Lincoff, A.M., Topol, E.J., Califf, R.M., Ohman, E.M. J. Am. Coll. Cardiol. (2001)